Overview
Ciitizen helped patients collect, organize, and share medical records held by different healthcare providers. Founded in 2017, it began with cancer patients and later expanded into rare diseases. The company treated access to the complete record as a prerequisite for both personal care and patient-authorized research. [1] [2]
Invitae acquired Ciitizen in 2021. In 2023, Invitae transferred the platform's assets to a new company led by members of the Ciitizen team. That successor became Citizen Health and continues to serve patients with rare diseases. The original acquisition and the later asset transfer are separate transactions. [3] [4]
Founding Story
Anil Sethi had built Gliimpse, a personal health record company acquired by Apple in 2016. He joined Apple, then left to work on Ciitizen after his sister Tania died of breast cancer. Her illness exposed the difficulty of gathering records scattered across clinicians and institutions. [5] [6]
Andreessen Horowitz identified Sethi, Premal Shah, and Brian Carlsen as co-founders in its 2018 investment post. Citizen Health also identifies Farid Vij as a Ciitizen co-founder. The available accounts do not establish how the founders met or fully reconcile their respective founding roles. [1] [2]
Sethi's concern was practical: patients could need pathology reports, laboratory results, and imaging from several facilities at once. “When Tania was sick, her doctors wanted to know a few things, like her labs,” he told CNBC, as reproduced by Healthcare Innovation. The company set out to help people request and assemble their own records. [5]
Timeline
- 2017: Sethi left Apple to start Ciitizen. [6]
- 2019: Ciitizen announced a $17 million Series A led by Andreessen Horowitz. It partnered with the Cholangiocarcinoma Foundation to offer early access. [7] [8]
- 2020: The foundation and Ciitizen promoted the Map It Forward research study and a virtual onboarding session. [9]
- 2021: Invitae acquired Ciitizen. Its annual report recorded approximately $308.3 million in consideration. [10]
- 2023: Invitae divested Ciitizen's assets to a new venture while retaining a minority stake. [3]
What They Built
A patient created an account and authorized Ciitizen to request records from identified providers. The company collected and organized information for the patient, who could share it with others. A 2019 preprint describes written requests signed by users and sent to their providers. The preprint's 30 beta users were recruited through personal connections, advocacy organizations, or a waitlist; it was not a representative population study. [11]
Ciitizen also worked with patient communities on research. For the Map It Forward study, the Cholangiocarcinoma Foundation invited patients to collect records and opt to contribute data. The 2020 onboarding event illustrates a distribution method: a disease-specific organization helped patients understand a process that involved both records access and a separate research choice. [9]
Market Position
Target Customers
Patients with cancer and later rare diseases faced records spread across specialists and facilities. Advocacy groups could help patients learn about the service, while researchers sought usable data from patients who consented. Those groups had related but different interests, making permission and clear boundaries central to the product. [2] [12]
Market Size
The reviewed sources do not establish Ciitizen's market share or a reliable addressable market. Rare disease communities can be small individually; that makes recruitment and complete longitudinal records valuable research questions, but does not establish a specific commercial return.
Competition
Ciitizen competed with manual patient requests, provider portals, and tools that gathered records. Sethi's earlier Gliimpse had become part of Apple's health-records work. Citizen Health, the later independent venture, now offers records collection and patient-facing tools, so a new entrant would face a direct successor rather than an empty market. [5] [13]
Business Model
The Cholangiocarcinoma Foundation offered Ciitizen's records service to patients at no charge. Ciitizen also supported research with patient permission, but the sources reviewed do not establish its historical revenue or contract economics. Citizen Health's current privacy policy describes a free patient service and potential fees from researchers for consented, de-identified data. That later policy should not be treated as proof of Ciitizen's exact historical terms. [9] [14]
Traction
Ciitizen's early records-access work documented requests on behalf of 30 beta users. Later, its partnership with the Cholangiocarcinoma Foundation provided early access and supported research onboarding. These examples show how the service operated; they do not establish its total user count or clinical impact. [11] [8]
Outcome and evolution
Invitae bought the platform
Invitae sought to combine patient-controlled clinical records with its genetic testing and data services. Its 2021 filing recorded approximately $87.4 million in cash and 6.3 million shares as part of the acquisition consideration. The actual accounting figure differs from the approximately $325 million announced transaction value; neither proves the return to any particular investor. [15] [10]
The platform changed hands again
In December 2023, Invitae said it had divested Ciitizen's assets as part of a plan to reduce cash spending. A new venture established by Ciitizen business leaders received the assets, and Invitae retained a minority interest. Invitae grouped that transaction with other cost reductions when estimating savings, so the reported savings cannot be attributed to the Ciitizen divestiture alone. [3]
The structural challenge is that collecting records and keeping permission meaningful require ongoing work across institutions. A platform may be useful to patients while also needing a buyer or research partner to finance that work. That is an interpretation of the product and ownership sequence; public evidence does not establish Ciitizen's standalone profitability or why Invitae chose this particular asset transfer. [11] [3]
Key Lessons
- Make access concrete. Ciitizen requested records from named providers on the patient's behalf. The work lay in gathering and organizing real records, not only giving patients a place to store files. [11]
- Treat research consent as a distinct choice. Map It Forward joined records collection to an optional research pathway through a trusted patient organization. [9]
- Follow the asset after acquisition. Invitae's later divestiture moved the platform into a new venture. Ownership changed twice while the service concept continued. [3]
Sources
- a16z: Ciitizen
- Citizen Health: About
- Invitae: Ciitizen divestiture
- Fierce Biotech: Citizen Health
- Healthcare Innovation: Anil Sethi
- AppleInsider: Ciitizen founding
- Ciitizen: Series A
- Ciitizen: foundation partnership
- Cholangiocarcinoma Foundation: onboarding
- Invitae: annual report
- Ciitizen: patient access preprint
- AJMC: patient-driven research
- Citizen Health: current service
- Citizen Health: privacy policy
- Invitae: acquisition announcement